ARE Alexandria Real Estate Equities Earnings and EPS analysis

Relative Growth: Rel. Growth:

Relative Strength: Rel. Strength:

Relative Valuation: Rel. Valuation:

Relative Profitability: Rel. Profitability: 25

EPS in 2026 (TTM): -$8.42

Last Report Period Date: Sep 30, 2026

As of November 2026, ARE's current EPS stands at -$8.42, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of -$8.44, which marks a drop compared to its EPS of $1.8 in 2024. ARE reported an EPS of -$3.74 for the quarterly report ending on Sep 30, 2026.

ARE earnings history

Historical annual and quarterly earnings per share (EPS) data for Alexandria Real Estate Equities

EPS (TTM)

-$8.42

EPS Growth YoY (Quarterly)

-171%

EPS (Quarterly)

-$3.74

EPS Growth (Quarterly)

-769.8%

For 2025, Alexandria Real Estate Equities's EPS was -$8.44, a drop of 568.9% from $1.8 in 2024. For the fiscal quarter that ended on Sep 30, 2026, the per-share earnings was -$3.74, showing a 171% decrease from the same quarter last year. For the twelve months ending September 2026, the EPS is -$8.42. For the year 2024, the yearly earnings per share was $1.8, marking an increase of 233.3% from 2023.

ARE EPS vs price chart

ARE EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

-171%

EPS growth YoY

-568.9%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Alexandria Real Estate Equities has registered a decrease in EPS of 171% during the last 12 months (YoY, quarterly).

ARE Earnings Waterfall

Breakdown of revenue, profit and net income for Alexandria Real Estate Equities

ARE Earnings vs Peers

What are the earnings of ARE compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
ALNY Alnylam Pharmaceuticals Inc	8.1	209.6%	N/A	N/A
BMY Bristol-Myers Squibb Company	14	178.7%	5.3%	N/A
AMGN AMGEN Inc	26.79	88.1%	5.6%	2.9%
ILMN Illumina Inc	35.21	171.1%	N/A	4.1%
PFE Pfizer Inc	40.69	-3.5%	-37.4%	-3.7%
LLY Lilly(Eli) & Company	46.79	95.6%	49.2%	27.5%
GILD Gilead Sciences Inc	N/A	1,700%	23.2%	132.8%
ARE Alexandria Real Estate Equities Inc	N/A	-568.9%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.